Study Stopped
Clinical studies stopped, pending funding
Multiple Cigarette Induced Changes in Hormone Function, Mood States and Behavior
1 other identifier
interventional
72
1 country
1
Brief Summary
The proposed clinical studies will analyze the interactions between nicotine, alterations in endocrine hormones, mood and cardiovascular measures. They also intend to examine the contribution of gender and menstrual cycle phase. These studies hypothesize that this novel focus on nicotine's rapid hormonal, cardiovascular and subjective effects will be important for developing novel biologic approaches to treatment for nicotine abuse and dependence as well as advancing our understanding of the neurobiology of nicotine reinforcement.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for not_applicable
Started Dec 2005
Longer than P75 for not_applicable
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
December 1, 2005
CompletedFirst Submitted
Initial submission to the registry
June 21, 2012
CompletedFirst Posted
Study publicly available on registry
July 10, 2012
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 1, 2016
CompletedStudy Completion
Last participant's last visit for all outcomes
December 1, 2016
CompletedJanuary 15, 2013
January 1, 2013
11 years
June 21, 2012
January 14, 2013
Conditions
Outcome Measures
Primary Outcomes (2)
Effects of Nicotine on the hypothalamic-pituitary-adrenal (HPA) axis
The investigators are examining the effects of smoked nicotine on serum nicotine levels and serum/plasma hormone levels.
From baseline to study completion (approximatley 8 months for females)
Effects of Nicotine on the hypothalamic-pituitary-gonadal (HPG) axis
The investigators are examining the effects of smoked nicotine on serum level nicotine and serum/plasma hormone levels.
From baseline to study completion (approximately 8 months for females)
Secondary Outcomes (2)
Effects of Nicotine on Mood States on the Visual Analog Scale
From baseline to study completion (approximately 8 months for females)
Effects of Nicotine on cardiovascular measures
From baseline to study completion (approximately 8 months for females)
Study Arms (2)
Female Smokers (Mid-Luteal Phase; cycle days 18-22)
ACTIVE COMPARATORFemale Smokers (Early Follicular Phase; cycle days 4-8)
ACTIVE COMPARATORInterventions
Two doses of nicotine will be utilized: a commercially available, high-yield nicotine cigarette (Marlboro Red; Phillip Morris brand) and a denicotinized cigarette (Murty Pharmaceuticals Inc., Lexington, KY). The high dose cigarettes contain 15.48 mg of nicotine and 16 mg of tar based on analysis by the Massachusetts Department of Public Health (MDPH, 1998). The low nicotine cigarettes contain 1.1 mg of nicotine and deliver 0.1 mg of nicotine and 2.8 mg of tar based on analyses provided by the manufacturer.
Eligibility Criteria
You may qualify if:
- Women between the ages of 18 and 40 who currently smoke at least 15 cigarettes every day, and who fulfill DSM-IV diagnostic criteria for nicotine dependence (305.10) will be eligible for participation.
- No evidence of clinically significant disease based upon complete medical history and physical examination by a qualified physician.
- Absence of DSM-IV Axis I Disorders other than nicotine dependence (305.10) as measured by the Structured Clinical Interview (SCID).
- Routine laboratory blood tests including complete blood count, electrolytes, BUN and creatinine, liver function test, hepatitis panel and urinalysis will be performed. Laboratory parameters must be within the normal range. HBsAg must be negative but study participants who have hepatitis serology consistent with previous exposure to Hepatitis A, Hepatitis B, or Hepatitis C, but who do not have clinical and biochemical evidence of acute infection, will be acceptable.
- Hematocrit levels ≥ 35%.
- Serum pregnancy test (hCG beta subunit) results must be negative within 24 hrs of the study day.
- Normal ECG.
- A mean Body Mass Index (ratio of weight (W) to height (H) squared; W/H2=kg/m2) will be calculated. Women with a mean Body Mass Index (BMI) between 18.0-27.0 will be accepted.
- Study participants must be able to read, understand instructions and provide a valid informed consent.
You may not qualify if:
- Women with any lifetime DSM-IV Axis I disorder other than nicotine dependence will be excluded.
- Women who are pregnant as determined by laboratory testing for serum beta hCG will be excluded.
- Women who use hormonal contraceptive medications will not be accepted for participation because this would confound the hormonal measures.
- Women with clinically significant medical disorders will be excluded.
- A mean Body Mass Index (ratio of weight (W) to height (H) squared; W/H2=kg/m2) will be calculated. Women with a mean Body Mass Index (BMI) outside of the range of 18.0-27.0 will be excluded.
- Treatment seeking study participants will not be selected but will be referred to local smoking cessation programs.
- Women taking any OTC medications on a regular basis (with the exception of multivitamin formulas) or prescription medications will be excluded.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Mclean Hospitallead
Study Sites (1)
Alcohol and Drug Abuse Research Center at McLean Hospital
Belmont, Massachusetts, 02478, United States
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Nancy K Mello, PhD
Mclean Hospital
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- NON RANDOMIZED
- Masking
- SINGLE
- Who Masked
- PARTICIPANT
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Director, Alcohol and Drug Abuse Research Center & Professor of Psychology (Neuroscience), Harvard Medical School
Study Record Dates
First Submitted
June 21, 2012
First Posted
July 10, 2012
Study Start
December 1, 2005
Primary Completion
December 1, 2016
Study Completion
December 1, 2016
Last Updated
January 15, 2013
Record last verified: 2013-01